{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:23:57Z","timestamp":1786119837335,"version":"build-2736575974"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1097\/wnf.0b013e31826538c7","type":"journal-article","created":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T16:47:30Z","timestamp":1346518050000},"page":"208-214","source":"Crossref","is-referenced-by-count":70,"title":["Efficacy, Tolerability, and Immunogenicity of OnabotulinumtoxinA in a Randomized, Double-Blind, Placebo-Controlled Trial for Cervical Dystonia"],"prefix":"10.1097","volume":"35","author":[{"given":"David","family":"Charles","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Brashear","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Hauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung-Ir","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee-Ming","family":"Boo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell F.","family":"Brin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-2-20210203","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1212\/WNL.41.7.1088","article-title":". Cervical dystonia: clinical findings and associated movement disorders.","volume":"41","author":"Jankovic","year":"1991","journal-title":"Neurology"},{"key":"R2-2-20210203","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/mds.870060206","article-title":"Idiopathic cervical dystonia: clinical characteristics.","volume":"6","author":"Chan","year":"1991","journal-title":"Mov Disord"},{"key":"R3-2-20210203","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1212\/01.wnl.0000311389.26145.95","article-title":". Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.","volume":"70","author":"Simpson","year":"2008","journal-title":"Neurology"},{"key":"R4-2-20210203","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0031-6997(25)06852-8","article-title":"The origin, structure, and pharmacological activity of botulinum toxin.","volume":"33","author":"Simpson","year":"1981","journal-title":"Pharmacol Rev"},{"key":"R5-2-20210203","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2958.1994.tb00396.x","article-title":"Mechanism of action of tetanus and botulinum neurotoxins.","volume":"13","author":"Montecucco","year":"1994","journal-title":"Mol Microbiol"},{"key":"R6-2-20210203","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/307457a0","article-title":". Acceptors for botulinum neurotoxin reside on motor nerve terminals and mediate its internalization.","volume":"307","author":"Dolly","year":"1984","journal-title":"Nature"},{"key":"R7-2-20210203","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1526-4610.2004.04007.x","article-title":"Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy.","volume":"44","author":"Durham","year":"2004","journal-title":"Headache"},{"key":"R8-2-20210203","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0041-0101(99)00153-1","article-title":"Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins.","volume":"38","author":"Welch","year":"2000","journal-title":"Toxicon"},{"key":"R9-2-20210203","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.pain.2003.10.008","article-title":". Subcutaneous administration of botulinum toxin A reduces formalin-induced pain.","volume":"107","author":"Cui","year":"2004","journal-title":"Pain"},{"key":"R10-2-20210203","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/PL00007848","article-title":"A randomized, double-masked, crossover comparison of the efficacy and safety of botulinum toxin type A produced from the original bulk toxin source and current bulk toxin source for the treatment of cervical dystonia.","volume":"249","author":"Naumann","year":"2002","journal-title":"J Neurol"},{"key":"R12-2-20210203","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1212\/WNL.45.9.1743","article-title":"Response and immunoresistance to botulinum toxin injections.","volume":"45","author":"Jankovic","year":"1995","journal-title":"Neurology"},{"key":"R13-2-20210203","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/mds.1226","article-title":". Cervical dystonia severity scale reliability study.","volume":"16","author":"OBrien","year":"2001","journal-title":"Mov Disord"},{"issue":"Suppl 8","key":"R15-2-20210203","doi-asserted-by":"crossref","first-page":"S109","DOI":"10.1002\/mds.20024","article-title":"Treatment of cervical dystonia with botulinum toxin.","volume":"19","author":"Jankovic","year":"2004","journal-title":"Mov Disord"},{"issue":"Suppl 1","key":"R16-2-20210203","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/PL00007812","article-title":"Evidence-based medicine in botulinum toxin therapy for cervical dystonia.","volume":"248","author":"Ceballos-Baumann","year":"2001","journal-title":"J Neurol"},{"key":"R17-2-20210203","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1212\/WNL.50.6.1624","article-title":"Mouse bioassay versus Western blot assay for botulinum toxin antibodies: correlation with clinical response.","volume":"50","author":"Hanna","year":"1998","journal-title":"Neurology"},{"key":"R18-2-20210203","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1136\/jnnp.66.5.612","article-title":"Comparison of mouse bioassay and immunoprecipitation assay for botulinum toxin antibodies.","volume":"66","author":"Hanna","year":"1999","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R19-2-20210203","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/mds.22157","article-title":". Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay.","volume":"23","author":"Brin","year":"2008","journal-title":"Mov Disord"},{"key":"R20-2-20210203","first-page":"337","article-title":"Efficacy and safety of a new bulk toxin of botulinum toxin in cervical dystonia: a blinded evaluation.","volume":"22","author":"Racette","year":"1999","journal-title":"Clin Neuropharmacol"},{"key":"R23-2-20210203","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1212\/01.wnl.0000183055.81056.5c","article-title":". Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia.","volume":"65","author":"Comella","year":"2005","journal-title":"Neurology"}],"container-title":["Clinical Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/WNF.0b013e31826538c7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T19:18:36Z","timestamp":1786043916000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00002826-201209000-00002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/wnf.0b013e31826538c7","relation":{},"ISSN":["0362-5664"],"issn-type":[{"value":"0362-5664","type":"print"}],"subject":[],"published":{"date-parts":[[2012,9]]}}}